Benjamin A. Weinberg

Oncology
3800 Reservoir Rd NW
Washington, DC 20007

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 77 publications

Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer.

Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer.

Journal: Research square
Published: July 10, 2026

Correction: Nerofe+ldDox releases c-Jun from nuclear ST2 to reprogram the immune microenvironment in mtKRAS tumors.

Correction: Nerofe+ldDox releases c-Jun from nuclear ST2 to reprogram the immune microenvironment in mtKRAS tumors.

Journal: Oncotarget
Published: April 24, 2026

Effects of Proglumide with Chemotherapy on the Pancreatic Tumor Microenvironment: Phase 1 PROGEM Trial.

Effects of Proglumide with Chemotherapy on the Pancreatic Tumor Microenvironment: Phase 1 PROGEM Trial.

Journal: Pharmaceutics
Published: January 31, 2026

Vascular Resection, Reconstruction, and Divestment in Pancreatoduodenectomy: Expanding Boundaries in Pancreatic Cancer Surgery.

Vascular Resection, Reconstruction, and Divestment in Pancreatoduodenectomy: Expanding Boundaries in Pancreatic Cancer Surgery.

Journal: Cancers
Published: January 17, 2026

Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy.

Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy.

Journal: Cancers
Published: January 08, 2026

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 07, 2026

Nerofe+ldDox releases c-Jun from nuclear ST2 to reprogram the immune microenvironment in mtKRAS tumors.

Nerofe+ldDox releases c-Jun from nuclear ST2 to reprogram the immune microenvironment in mtKRAS tumors.

Journal: Oncotarget
Published: December 29, 2025

Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data.

Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data.

Journal: Journal for immunotherapy of cancer
Published: December 01, 2025

Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.

Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.

Journal: Oncogene
Published: November 05, 2025

CXCR4 mRNA overexpression: an indicator of poor survival and predictor of response to immune checkpoint inhibitors in patients with metastatic colorectal cancer.

CXCR4 mRNA overexpression: an indicator of poor survival and predictor of response to immune checkpoint inhibitors in patients with metastatic colorectal cancer.

Journal: BMJ oncology
Published: October 12, 2025

Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer.

Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer.

Journal: NPJ precision oncology
Published: October 09, 2025

Sex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes.

Sex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes.

Journal: Cell reports. Medicine
Published: July 28, 2025
Showing 1-12 of 77

Last Updated: 09/26/2026